|
|
 |
|
Viewing report
|
|
|
|
Alzheimer's Disease: Markets, Pipeline and Opportunities 2009
BioPharm Reports (VennBio Ltd.), April 2009, Pages: 110
Overview: Today's armoury of approved drugs for the treatment of Alzheimer's Disease (AD) largely depends on just five therapeutic agents. In 2007, three of these agents represented 88% of global sales, in a market that this report estimates exceeded $6 billion in 2008. There are presently no cures for AD, and current drugs are only able to treat some of the symptoms in some people, with benefits that are often short-lived. Hope is being placed in future disease-modifying drugs, but this report shows that 80% of these candidates are still at Phases I and II. With the relatively recent suspension of two prominent potential disease-modifying Phase III candidates, immediate hopes for these kinds of new-generation drugs now rest on just two to three late-stage candidates. Historically, efforts to develop drugs to treat neurodegenerative disease have demonstrated significant risk, and failure rates have been high. While this has focused companies’ efforts on targeting the underlying disease mechanisms, alternative strategies have been stimulated by studies showing that some of the changes found in AD mirror those seen in some other conditions.
This report estimates that 30% of current Phase III trials are investigating drugs already approved for other indications. A high proportion of Phase III studies are also investigating new formulations of existing approved drugs or new drug combinations. The AD market offers high growth potential, particularly as more effective treatments are developed. It is also evident that therapeutic opportunities in this field are still wide open, as unmet medical need grows. This report gives a comprehensive overview of the market performance of approved AD drugs, globally, regionally and in the US. The current pipeline, drug development strategies and opportunities in this field are also reviewed.
Alzheimer's Disease: In 2006 it was estimated that 27 million people globally were suffering from AD – a figure that is expected to quadruple to more than 100 million by 2050, if a cure is not found. Direct and indirect costs of AD and other dementias in the US are more than $148 billion annually, with worldwide costs for dementia care estimated at $315 billion annually. The 2003 World Health Report indicated that dementia contributed 11.2% of years lived with disability in people aged 60 years and older. This is higher than strokes (9.5%), musculoskeletal disorders (8.9%), cardiovascular disease (5.0%) and all forms of cancer (2.4%).
Markets
The global AD drug market has grown steadily over the last decade, from around $500 million in 1999 to over $6 billion in 2008, which is an average increase of more than 33% per year. In the last five years, the average growth rate was 23%. Just five approved drugs dominate global sales, three of which represented 88% of global sales in 2007.
Pipeline
In contrast to the handful of approved drugs for the treatment of AD – where just five agents account for an estimated 95%+ of drug sales – there are more than 178 candidate drugs or candidate treatments currently in the clinical pipeline. Of these, 82% are at Phases I and II. In addition to drugs aimed at targeting AD directly, more than 35 other drug classes are being investigated in an effort to development other strategies for treating AD and its symptoms.
Questions answered in this report:
- Which AD drugs are the market leaders?
- How are the trends in the sales of AD drugs developing on a global and regional basis?
- What are the sales of individual AD drugs on a global and (where available) regional basis?
- What are the growth rates and global sales of AD Drugs?
- What are the forward projections of market growth in the AD field?
- What strategies are companies taking in the development of new AD drugs?
- What are the technical and commercial drivers for drug development in the AD field?
- What types of potential disease-modifying drugs are being developed to target AD, and where are they in the development pipeline?
- What therapeutic classes are being investigated in an effort to identify `new-use´ applications or repurposing opportunities?
- What drugs classes are currently in the AD development pipeline?
- What opportunities are available in the AD therapeutics field?
Customers who bought this item also bought
Alzheimer Disease - New Drugs, Markets and Companies
Chinese Markets for Alzheimer Disease Drugs
Thought Leader Insight & Analysis: Alzheimer's Disease
Treatment Algorithms 2002: Alzheimer's Disease - Aricept: the physicians choice
Drugs of Tomorrow: Alzheimer’s Disease - Ebixa Set to Expand Billion Dollar Market
Market Dynamics 2001: Alzheimer''s Disease - An expanding market driven by Aricept
CNS Drug Discoveries: Alzheimer's Disease Chapter
Global Markets for Alzheimer's Disease Medications 2005
Alzheimers and Parkinsons Disease - Global Strategic Business Report
Global Alzheimer Drugs Market: An Analysis
Neurodegenerative Disease: The Growing Market for Drugs used in the Treatment of Alzheimer's, Parkinson's and other Neurodegenerative Conditions
Alzheimer's Disease Biomarkers, 2009
|
|
|
|
